NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PomDoctor Ltd. (NASDAQ: POM) between October 9, 2025 and December 11, 2025, inclusive (the “Class Period”), of the important April 7, 2026 lead plaintiff deadline. SO WHAT: If you purchased PomDoctor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...

KD SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Kyndryl (KD) Investors of Securities Class Action Deadline on April 13, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Kyndryl To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Kyndryl] between August 7, 2024 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faru ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BlackRock TCP To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in BlackRock TCP between November 6, 2024 and January 23, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 26, 2026 (GLOBE NEWSWI ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Paysafe Limited due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by April 7, 2026 [3]. Group 1: Allegations Against Paysafe - The complaint alleges that Paysafe and its executives made false or misleading statements and failed to disclose significant risks, including exposure to a high-risk client and understated credit loss reserves [5]. - Specific issues cited include difficulties in banking services due to higher risk Merchant Category Codes, which are likely to negatively impact revenue growth and financial guidance for fiscal year 2025 [5]. - The allegations suggest that Paysafe's positive statements regarding its business operations were materially misleading [5]. Group 2: Financial Performance - On November 13, 2025, Paysafe reported third-quarter financial results with revenue of $433.8 million, missing consensus estimates by $5.8 million, and a net loss of $87.7 million, a significant increase from a net loss of $12.98 million in the prior year [6]. - The company revised its full-year 2025 revenue expectations to $17 million at the midpoint and adjusted EPS to $0.50 at the midpoint [6]. - The credit loss expense for the quarter was reported at $13,220, primarily due to expected chargebacks related to a specific merchant, with write-offs of $9,924 attributed to irrecoverable amounts in the Merchant Solutions segment [7]. Group 3: Market Reaction - Following the financial report, Paysafe's stock price fell by $2.80, or 27.6%, closing at $7.36 per share on unusually heavy trading volume [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Navan, Inc. due to allegations of violations of federal securities laws related to misleading statements in the company's IPO documents [4][6]. Group 1: Legal Action and Claims - A federal securities class action has been filed against Navan, with a deadline of April 24, 2026, for investors to seek the role of lead plaintiff [4]. - The complaint alleges that Navan and its executives made false and misleading statements and failed to disclose increased "sales and marketing" expenses at the time of the IPO [6]. - The value of Navan's shares has declined significantly, trading as low as $9.01 per share, which represents a decline of over 60% from the offering price [7]. Group 2: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses exceeding the IPO price to contact them to discuss their legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Navan's conduct [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Agilon health To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Agilon health between February 26, 2025 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - Fe ...

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Arcellx, Inc. to Gilead Sciences, Inc. to assess the adequacy of the price and process involved in the transaction [1] Group 1: Proposed Transaction Details - Under the terms of the proposed sale, shareholders of Arcellx will receive $115.00 per share in cash, along with one contingent value right of $5.00 per share contingent on achieving certain milestones [1] - The investigation aims to determine whether the proposed consideration undervalues Arcellx and if the process leading to this valuation was adequate [1] Group 2: Legal Rights and Actions - Shareholders who believe the transaction undervalues the company are encouraged to discuss their legal rights with Kahn Swick & Foti, LLC [1] - The transaction is structured as a tender offer, indicating that timing may be critical for shareholders [1]

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recov ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Varonis To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Varonis between February 4, 2025 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Faruq ...

Core Viewpoint - BellRing Brands, Inc. is facing a class action lawsuit alleging that the company misrepresented its sales growth as being driven by consumer demand, while in reality, it was primarily due to inventory stockpiling by key customers [3]. Company Overview - BellRing Brands, Inc. trades on the NYSE under the ticker BRBR and is currently under scrutiny due to allegations of misleading investors regarding its sales performance during the class period from November 19, 2025, to August 4, 2025 [1]. Allegations of Misrepresentation - The lawsuit claims that BellRing attributed its sales growth to "organic growth," "distribution gains," and "strong macro tailwinds around protein," while downplaying competitive pressures [3]. - It is alleged that the actual sales were not reflective of increased consumer demand but were instead driven by customers stockpiling inventory [3]. Impact of Competitive Pressures - On May 6, 2025, BellRing disclosed that several key retailers had reduced their inventory levels, which was expected to negatively impact sales growth, leading to a significant drop in share price by approximately 19% [4]. - Following a disappointing sales outlook reported on August 4, 2025, BellRing's share price fell by about 33%, indicating a severe market reaction to the news of increased competition and reduced sales expectations [5]. Legal Proceedings - The deadline for investors to seek lead plaintiff status in the class action is March 23, 2026, and courts typically appoint individual investors as lead plaintiffs [2].